Prostaglandin I2-mediated upregulation of 125I-LDL-receptor binding by isradipine in normo- and hypercholesterolemic rabbits in vivo

Prostaglandins

Volumn 52, Issue 2, 1996, Pages 77-91

  Sinzinger, Helmut ^a,b   Lupattelli, Graziana ^c   Kritz, H ^c   Fitscha, P ^c   O'Grady, John ^c  

^a Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

^b Wilhelm Auerswald Atherosclerosis   (Austria)

^c NONE

Author keywords

isradipine; LDL; Prostacyclin; rabbits

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; IODINE 125; ISRADIPINE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROSTACYCLIN; DIAGNOSTIC AGENT; LIPOPROTEIN; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERCHOLESTEROLEMIA; ISOTOPE LABELING; LIPOPROTEIN METABOLISM; LIVER METABOLISM; MALE; NONHUMAN; RABBIT; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; HUMAN; LIVER; METABOLISM; PHYSIOLOGY; TIME; UPREGULATION;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; EPOPROSTENOL; HUMANS; HYPERCHOLESTEROLEMIA; IODINE RADIOISOTOPES; ISRADIPINE; LIPOPROTEINS; LIPOPROTEINS, LDL; LIVER; MALE; RABBITS; RECEPTORS, LDL; TIME FACTORS; UP-REGULATION;

EID: 0030201165     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/0090-6980(96)00054-8     Document Type: Article

References (48)

1. 1. Jackson, C.L., Bush, R.C., and Bowyer, D.E. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 80:17-26. 1989.
2. ++-antagonist lanthanum. Possible role of calcium in atherogenesis. J Clin Invest 65:967-81. 1980.
3. 3. Ohata, I., Sakamoto, N., Nagano, K., and Maeno, H. Low-density lipoprotein lowering and high density lipoproteins elevating effects of nicardipine in rats. Biochem Pharmacol 33:2199-205. 1984.
4. 4. Sugano, M., Makashinma, Y., and Matsushima, T. Suppression of atherosclerosis in cholesterol fed rabbits by diltiazem injection. Arteriosclerosis 6:237-41. 1986.
5. 5. Pool, P.E., Seagren, S.C., and Salel, A.F. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 56:86H-91H. 1985.
6. 6. Rauramaa, R., Taskinen, E., Seppanen, K., Rissanen, V., Salonen, R., Venalainen, J.M., and Salonen, J.T. Effects of calcium antagonist treatment on blood pressure, lipoproteins and prostaglandins. Am J Med 84:93-7. 1988.
7. 7. Stein, G.H., Matthews, K., Bannatyne, R.E., Quay, G., Lopez, L., and McCarley, D. Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients. J Cardiovasc Pharmacol 15:S90-S2. 1990.
8. 8. Mayer, O., Polivkova, H., and Rottenborn, J. Isradipine in the treatment of hypertension. Some additional effects observed during a one-year study. Am J Hypertens 4:140S-3S. 1991.
9. 9. Lacourciere, Y., Gagne, C., Brun, D., Poirier, L., Dion, D., and Yardley, C. Beneficial effects of the calcium antagonist isradipine on apolipoproteins in hypertensive patients. Am J Hypertens 4:181S-4S. 1991.
10. 10. Samuel, P. Effect of isradipine, a new calcium antagonist on the lipid profile in patients with hypertension. Cor Vasa 32:35-41. 1990.
11. 11. Psaty, B.M., Heckbert, S.R., Koepsell, T.D., Siscovick, D.S., Raghunathan, T.E., Weiss, N.S., Rosendaal, F.R., Lemaitre, R.N., Smith, N.L., and Wahl, P.W. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274:620-5. 1995; Comment in: JAMA 274:654-5. 1995.
12. 11. Psaty, B.M., Heckbert, S.R., Koepsell, T.D., Siscovick, D.S., Raghunathan, T.E., Weiss, N.S., Rosendaal, F.R., Lemaitre, R.N., Smith, N.L., and Wahl, P.W. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274:620-5. 1995; Comment in: JAMA 274:654-5. 1995.
13. 12. Furberg, C.D., Psaty, B.M., and Meyer, J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326-31. 1995; Comment in: Circulation 92:1068-73. 1995; Comment in: Circulation 92:1074-8. 1995; Comment in: Circulation 92:1079-82. 1995.
14. 12. Furberg, C.D., Psaty, B.M., and Meyer, J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326-31. 1995; Comment in: Circulation 92:1068-73. 1995; Comment in: Circulation 92:1074-8. 1995; Comment in: Circulation 92:1079-82. 1995.
15. 12. Furberg, C.D., Psaty, B.M., and Meyer, J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326-31. 1995; Comment in: Circulation 92:1068-73. 1995; Comment in: Circulation 92:1074-8. 1995; Comment in: Circulation 92:1079-82. 1995.
16. 12. Furberg, C.D., Psaty, B.M., and Meyer, J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326-31. 1995; Comment in: Circulation 92:1068-73. 1995; Comment in: Circulation 92:1074-8. 1995; Comment in: Circulation 92:1079-82. 1995.
17. 125I-low-density lipoprotein-entry in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 17:546-50. 1991.
18. 14. Skepper, J.N., and Kappagoda, C.T. The effect of concurrent administration of isradipine on the development of fatty streaks in the cholesterol-fed rabbit: a morphometric study. Atherosclerosis 96:17-31. 1992.
19. 15. Sinzinger, H., Virgolini, I., O'Grady, J., Keiler, A., Lupattelli, G., Angelberger, P., and Molinari, E. Aspirin abolishes the decreased low-density lipoprotein (LDL) entry into the rabbit arterial wall induced by the calcium channel blocker isradipine. Eicosanoids 5:13-6. 1992.
20. 16. Virgolini, I., Angelberger, P., Lupattelli, G., Li, S.R., Pidlich, J., Molinari, E., and Sinzinger, H. Comparison of different methods for LDL-isolation and radioiodination on liver LDL-receptor binding in vitro. Int J Rad Appl Instrum 18:513-7. 1991.
21. 17. McFarlane, A.S. Efficient tracer labelling of proteins with iodine. Nature 182:53-8. 1958.
22. 18. Moncada, S., Gryglewski, R.J., Bunting, S., Vane, J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-5. 1976.
23. 19. Sinzinger, H. Antiatherogenic effects of Lomir/Dyna Circ (isradipine). Sandorama 4: 5-9. 1991.
24. 20. Daugherty, A., Rateri, D.L., Schonfeld, G., and Sobel, B.E. Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol 91:113-8. 1987.
25. 2+ blocking agents on the metabolism of low-density lipoproteins in human skin fibroblasts. Biochem Biophys Res Commun 107:217-24. 1982.
26. 22. Stein, O., Leitersdorf, E., and Stein, Y. Verapamil enhances receptor-mediated endocytosis of low-density lipoproteins by aortic cells in culture. Arteriosclerosis 5:35-44. 1985.
27. 23. Stein, O., and Stein, J. Effect of verapamil on cholesteryl ester hydrolysis and reesterification in macrophages. Arteriosclerosis 7:578-84. 1987.
28. 24. Corsini, A., Granata, A., Fumagalli, R., and Paoletti, R. Calcium antagonists and low-density lipoproteins metabolism by human fibroblasts and by human hepatoma cell line Hep-G2. Pharmacol Res Commun 18:1-16. 1986.
29. 25. Filipovic, I., and Buddecke, E. Calcium channel blockers stimulate LDL receptor synthesis in human skin fibroblasts. Biochem Biophys Res Commun 136:845-50. 1986.
30. 26. Brown, M.S., and Goldstein, J.L. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest 72:743-7. 1983.
31. 27. Mahley, R.W., and Innerarity, T.L. Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta 737:197-222. 1983.
32. 28. Steinberg, D. Lipoproteins and atherosclerosis. A look back and a look ahead. Arteriosclerosis 3:283-301. 1983.
33. 68Ga-DTPA-LDL: a potential radiopharmaceutical for in-vivo imaging of low-density lipoprotein receptor activity with PET. J Nucl Med 29:848-53. 1988.
34. 30. Vallabhajosula, S., Gilbert, H.S., Goldsmith, S.J., Paidi, M., Hanna, M.M., and Ginsberg, H.N. Low-density lipoprotein (LDL) distribution shown by 99mtechnetium-LDL imaging in patients with myeloproliferative diseases. Ann Intern Med 110:208-13. 1989.
35. 31. Hay, R.V., Fleming, R.M., Ryan, J.W., Williams, K.A., Stark, V.J., Lathrop, K.A., and Harper, P.V. Nuclear imaging analysis of human low-density lipoprotein biodistribution in rabbits and monkeys. J Nucl Med 32: 1239-45. 1991.
36. 32. Weiss, K., Fitscha, P., O'Grady, J., and Sinzinger, H. Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production. Thromb Res 54: 311-7. 1989.
37. 1. New aspects on pharmacology, metabolism and clinical efficacy (Diehm, C., Sinzinger, H. and Rogatti, W., eds) Springer-Verlag, Heidelberg, 1991, pp 39.
38. 34. Virgolini, I., Müller, C., Hermann, M., Schütz, W., and Sinzinger, H. Evaluation of prostaglandin-receptors in human and rat liver: interspecies differences at the prostaglandin receptor level. Prostaglandins 36:807-18. 1988.
39. 1 on low-density lipoprotein apo-B-receptor binding in human, rat and swine liver in vitro. Prostaglandins 42:81-93. 1991.
40. 36. Sinzinger, H., and Virgolini, I. Nuclear medicine and atherosclerosis. Eur J Nucl Med 17:160-78. 1990.
41. 37. Lees, R.S., Garabedian, H.D., Lees, A.M., Schuhmacher, D.J., Miller, A., Isaacsohn, I.L., Derksen, A., and Strauss, H.W. Technetium-99m low-density lipoproteins: preparation and biodistribution. J Nucl Med 26: 1056-62 and 27:1377. 1985.
42. 38. Rosen, J.M., Butler, S.P., Meinken, G.E., Wang, T.S., Ramakrishnan, R., Srivastava, S.C., Alderson, P.O., and Ginsberg, H.N. Indium 111-labeled LDL: a potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. J Nucl Med 31: 343-50. 1990.
43. 39. Vallabhajosula, S., Paidi, M., Badimon, J.J., Le, N.A., Goldsmith, S.J., Fuster, V., and Ginsberg, H.N. Radiotracers for low-density lipoprotein biodistribution studies in vivo: technetium 99m low-density lipoprotein versus radioiodinated low-density lipoprotein preparations. J Nucl Med 29:1237-45. 1988.
44. 40. Gross, M.D., Skinner, R.W.S., Schwendner, S.W., Deforge, L.E., Counsell, R.E., and Newton, R.S. Indium 111-DTPA low-density lipoprotein (LDL) imaging of LDL-receptor activity. J Nucl Med 30:768-70. 1989.
45. 41. Lupattelli, G., Virgolini, I., Sinzinger, H., Ciuffetti, G., Siepi, D., Orecchini, G., Pistola, L., and Ventura, S. Studio in vivo del recettore epatico per le LDL mediante reiniezione di lipoproteine autologhe maracata con I. Giornale della Arteriosclerosi 15:127-31. 1990.
46. 42. Lupattelli, G., Virgolini, I., Li, S.R., and Sinzinger, H. Low-density lipoprotein receptors: preliminary results on "in-vivo" study. Wien Klin Wochenschr 103:462-6. 1991.
47. 43. Lupattelli, G., Virgolini, I., Rauscha, F., and Sinzinger, H. Quantitative imaging of human liver low-density lipoprotein (LDL) receptors in vivo. In: Radioaktive Isotope in Klinik und Forschung (Höfer, R., Bergmann, H. and Sinzinger, H., eds) Schattauer-Verlag, Stuttgart, 1991, pp148.
48. 44. Kovanen, P.T., Brown, M.S., Basu, S.K., Bilheimer, D.W., and Goldstein, J.L. Saturation and suppression of hepatic lipoprotein receptors: a mechanism for the hypercholesterolemia of cholesterol-fed rabbits. Proc Natl Acad Sci USA 78:1396-400. 1981.